Loading page
Loading page
Loading substance route
Effects vary widely by individual, dose, and context.
These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
Methaqualone is described as extremely addictive with high abuse potential. Psychological dependence is very common with regular use, particularly at doses over 600 mg per day. Users report severe cravings for the drug persisting for extended periods after cessation.
Physical dependence develops rapidly, with daily use of even moderate doses producing addiction within a couple of weeks. Withdrawal symptoms include restlessness, irritability, insomnia, tremors, nausea, vomiting, abdominal cramps, and muscle twitches. Severe withdrawal can involve mental confusion, delirium, hallucinations, high fever, and epileptic-like seizures that can be fatal.
Human lethal dose is approximately 8,000 mg, though this varies considerably with individual tolerance. Some users have survived doses up to 20,000-22,000 mg while others have died from as little as 8,000 mg per day. A dose as low as 2,000 mg can induce coma when combined with alcohol. Fatal overdoses were being reported as early as 1962.
| Species | Route | Value |
|---|---|---|
| mouse | oral | 1250 mg/kg |
| rat | oral | 326 mg/kg |
| rat | oral | 255 mg/kg |
Respiratory depression is a significant effect at higher doses and can progress to respiratory arrest in overdose; the combination with other depressants substantially increases this risk.
Cardiac effects including reduced heart rate and blood pressure occur during use; cardiac arrest is possible in severe overdose.
Kidney failure has been reported as a consequence of severe overdose.
Paranoia, panic, and anxiety can occur during use, particularly at certain doses. More severe psychiatric effects including mental confusion, delirium, nightmares, and hallucinations are primarily associated with withdrawal rather than acute intoxication.
Seizures represent a significant risk with methaqualone both in overdose and during withdrawal from chronic use. Convulsions have been documented in both circumstances, with withdrawal seizures being potentially fatal. The drug has anticonvulsant properties at normal doses, but tolerance develops to this effect with repeated administration.
Methaqualone was first synthesized in India in 1951 by M.I. Gujral as part of a research program seeking antimalarial compounds. Although the substance proved ineffective against malaria, researchers identified its hypnotic properties by 1955. A subsequent pharmacological study in 1957 confirmed…
Classified as a prohibited substance with no recognized medical value. Possession, manufacture, and distribution require a license.
Controlled under the Controlled Drugs and Substances Act. Requires a valid prescription or license to legally possess. Pharmaceutical methaqualone remains available through legitimate prescription channels.
Designated as a 'powerful drug' in June 1964 after reports of widespread nonmedical use. Containers must display 'powerful' in red lettering. Sales restricted to pharmacies with mandatory record-keeping including recipient name, address, occupation, drug purpose, and transfer date. Prohibited for sale to individuals under 14 or those deemed unlikely to handle the substance responsibly.
Initially controlled under the Drugs Prevention of Misuse Act 1970, making importation without Home Office license and unauthorized possession criminal offenses. The Misuse of Drugs Act 1971 was amended in July 1973 to include methaqualone, strengthening controls and increasing penalties. Regulatory measures such as handwritten prescription requirements were implemented.
Controlled under the Suchtmittelgesetz (Austrian Narcotics Act). Possession, production, and sale are prohibited without authorization.
Controlled under the Betäubungsmittelgesetz. Manufacturing, importing, possessing, selling, or transferring without license is prohibited. Initially sold over-the-counter in the 1960s before prescription requirements were introduced in 1963 following reports of misuse.
Specifically listed as a controlled substance under Verzeichnis A of Swiss narcotics legislation. Unlike some jurisdictions, medicinal use remains permitted under appropriate licensing.
Originally approved by the FDA in 1965 with minimal controls. Placed in Schedule II in 1973 following concerns about abuse potential. Moved to Schedule I in June 1984 after Congress passed legislation specifically targeting methaqualone. Under current law, it is illegal to manufacture, buy, possess, or distribute without a DEA license. Lemmon, the final domestic manufacturer, ceased production in November 1983.
11 sources cited
